PURPOSE: Sometimes, we encounter the cases of pulmonary metastasectomy whom additional foci in the lung have developed soon after surgery. This failure is due to the lack of notice to dormant foci. The interval for re-evaluation of these foci might be necessary prior to pulmonary metastasectomy. In this study, we investigated the best timing of pulmonary metastasectomy.
METHODS: This retrospective study included 68 patients who underwent curative pulmonary resection for metastatic lung tumor in our department between August 2000 and November 2005. The interval from detection of pulmonary metastasis until pulmonary metastasectomy, the disease-free interval, and survival were evaluated.
RESULTS: The 68 patients who underwent pulmonary metastasectomy consisted of 46 males and 22 females. The patients’ ages ranged from 3 to 82 years, with a mean age of 59.5 years. The mean DFI was 32.9 months and the mean interval from detection of pulmonary metastasis until pulmonary metastasectomy was 5.9 months. The overall 1-year, 3-year and 5-year survival rates after pulmonary metastasectomy were 91.2%, 75.7% and 75.7%, respectively. We divided the patients into two groups according to the interval from detection of pulmonary metastasis until pulmonary metastasectomy. Thirty-five patients underwent pulmonary metastasectomy within 3 months after detection of pulmonary metastasis (Group S) and 33 patients did so beyond 3 months (Group L). The gender, age, DFI, surgical techniques, number of metastases and survivals were also evaluated. There were no significant differences in gender, age, DFI, number of metastases, surgical techniques and primary organs between Groups S and L. Significantly longer survival was observed in Group L than in Group S.
CONCLUSION: There were many cases of early relapse after metastasectomy when the interval from detection of pulmonary metastasis until pulmonary metastasectomy was short.
CLINICAL IMPLICATIONS: Clinical follow-up and re-evaluation for at least three months prior to metastasectomy would improve the prognosis of patients.
DISCLOSURE: Yoshimasa Maniwa, No Financial Disclosure Information; No Product/Research Disclosure Information